Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. https://doi.org/10.1016/S1470-2045(19)30388-2.

Article  CAS  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684.

Article  CAS  Google Scholar 

Switzer B, Puzanov I, Skitzki JJ, Hamad L, Ernstoff MS. Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract. 2022;18(5):335–51. https://doi.org/10.1200/OP.21.00686.

Article  Google Scholar 

Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res. 2021;27(19):5289–98. https://doi.org/10.1158/1078-0432.CCR-21-1171.

Article  CAS  Google Scholar 

Kooragayala K, Lou J, Hong YK. Adoptive cellular therapy for metastatic melanoma: the road to commercialization and treatment guidelines for clinicians. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12528-7.